secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023210
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q3 cash falls to $194.3M; revenue $16.9M; restructuring $7.1M; IND targets set for 2023
--------------------------------------------------------------------------------

- Cash and investments $194.3M as of Sep 30, 2022, down from $305.2M at Dec 31, 2021.
- Revenue $16.9M for Q3 2022 vs $17.6M for Q3 2021, down ~4%.
- R&D expense $30.4M, G&A $10.5M; restructuring charges $7.1M in Q3.
- IND for CX-2051 and CX-801 expected H2 2023; CX-2029 sqNSCLC data update Q4 2022.
- Company restructuring announced July 2022 to be completed by end of 2022; total ~$7.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017022023210/0000950170-22-023210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017022023210/ctmx-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer